imatinib mesylate has been researched along with Abnormal Karyotype in 5 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 4 (80.00) | 24.3611 |
| 2020's | 1 (20.00) | 2.80 |
| Authors | Studies |
|---|---|
| Cai, Y; Chen, X; Chen, Y; Guo, Y; Liu, C; Yang, W; Zhang, L; Zhu, X; Zou, Y | 1 |
| Baurmann, H; Casper, J; Cross, NCP; Dang, TA; Dietze, L; Döhner, K; Fabarius, A; Haferlach, C; Haferlach, T; Hänel, A; Hochhaus, A; Hofmann, WK; Jawhar, M; Lathan, B; Link, H; Lotfi, S; Maywald, O; Metzgeroth, G; Mielke, S; Müller, L; Naumann, N; Panse, J; Platzbecker, U; Prümmer, O; Reiter, A; Schwaab, J; Thomssen, H; Töpelt, K; Vieler, T | 1 |
| Blanco, ML; Oñate, G; Pratcorona, M | 1 |
| Capra, ME; Fogliatto, LM; Koshiyama, DB; Oliveira, CA; Paskulin, GA; Rosa, RF; Vanelli, T; Zen, PR | 1 |
| Bektas, O; Bozkurt, S; Buyukasik, Y; Goker, H; Inanc, A; Kansu, E; Uz, B | 1 |
1 trial(s) available for imatinib mesylate and Abnormal Karyotype
| Article | Year |
|---|---|
Imatinib in myeloid/lymphoid neoplasms with eosinophilia and rearrangement of PDGFRB in chronic or blast phase.
Topics: Abnormal Karyotype; Adult; Aged; Aged, 80 and over; Blast Crisis; Disease-Free Survival; Eosinophilia; Female; Follow-Up Studies; Gene Rearrangement; Hematologic Neoplasms; Humans; Imatinib Mesylate; Male; Middle Aged; Receptor, Platelet-Derived Growth Factor beta; Reverse Transcriptase Polymerase Chain Reaction; Risk Factors; Sex Factors; Survival Rate | 2017 |
4 other study(ies) available for imatinib mesylate and Abnormal Karyotype
| Article | Year |
|---|---|
Long-term safety and efficacy of imatinib in pediatric patients with chronic myeloid leukemia: single-center experience from China.
Topics: Abnormal Karyotype; Adolescent; Anorexia; Antineoplastic Agents; Child; Child, Preschool; China; Drug Evaluation; Female; Follow-Up Studies; Fusion Proteins, bcr-abl; Growth Disorders; Humans; Imatinib Mesylate; Infant; Kaplan-Meier Estimate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Leukocyte Count; Male; Musculoskeletal Diseases; Progression-Free Survival; Protein Kinase Inhibitors; Remission Induction; Retrospective Studies; Treatment Outcome | 2021 |
Acquisition of Inv(16)(p13q22) in a blast crisis of chronic myeloid leukemia: case report.
Topics: Abnormal Karyotype; Adult; Antineoplastic Agents; Blast Crisis; Chromosome Inversion; Chromosomes, Human, Pair 16; Dasatinib; Female; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Oncogene Proteins, Fusion; Protein Kinase Inhibitors; Translocation, Genetic; Trisomy | 2019 |
Cytogenetic response to imatinib treatment in Southern Brazilian patients with chronic myelogenous leukemia and variant Philadelphia chromosome.
Topics: Abnormal Karyotype; Adolescent; Adult; Aged; Antineoplastic Agents; Benzamides; Brazil; Chromosomes, Human; Disease-Free Survival; Drug Resistance, Neoplasm; Female; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Philadelphia Chromosome; Piperazines; Prognosis; Protein Kinase Inhibitors; Pyrimidines; Retrospective Studies; Translocation, Genetic; Treatment Outcome; Young Adult | 2013 |
Prognostic importance of additional cytogenetic anomalies in chronic myeloid leukemia.
Topics: Abnormal Karyotype; Adult; Aged; Antineoplastic Agents; Benzamides; Chromosome Aberrations; Cytogenetic Analysis; Female; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Piperazines; Prognosis; Pyrimidines; Treatment Outcome | 2013 |